PCA50941

PCA50941 is a 1,4-dihydropyridine derivative, used for treatment for cardiovascular disease. In Vitro: PCA50941 (1 μM) shifts the I-V relationship of whole-cell Ca²⁺ currents by about 5-10 mV towards more hyperpolarizing potentials. PCA50941 increases further the K(+)-evoked peak to 655 nM. In the presence of 5 mM Ca²⁺, PCA50941 increases the [Ca²⁺] peaks to 427 nM. PCA50941 potentiates the release of catecholamines from perfused bovine adrenal glands evoked by 30 s pulses of 17.7 mM K⁺ in a manner dependent on the [Ca²⁺]o^[1]. In Vivo: PCA50941 (10-120 μM) by intracoronary injection, causes smaller reductions of coronary blood flow (CBF) in goats. PCA50941 (10-300 μM/min) does not modify CBF nor the other hemodynamic variables recorded by i.v. infusions in 4 goats. Intravenous infusion of PCA50941 (100 microg/min) reverses the hemodynamic variables from the shock state to control values within 20 min in 5 of 6 animals^[2].